Related Experiment Videos
Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase
F Boccardo1, A Rubagotti, L Canobbio
1Department of Medical Oncology II, National Institute for Cancer Research, Genoa, Italy.
Tumori
|December 23, 1998
Summary
Interleukin-2 (IL-2) and interferon (IFN) showed limited effectiveness for advanced renal cell carcinoma (RCC). New therapeutic strategies are needed for this challenging cancer.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Advanced renal cell carcinoma (RCC) presents significant therapeutic challenges.
- Interleukin-2 (IL-2) and interferon (IFN) are immunomodulatory agents explored for cancer treatment.
Purpose of the Study:
- To evaluate the therapeutic efficacy of IL-2 and IFN, as monotherapy or in combination, for advanced RCC.
- To compare treatment outcomes in comparable patient groups.
Main Methods:
- Randomized trial design to minimize selection bias.
- Patients received IL-2 alone, IFN alone, or a combination of both IL-2 and IFN.
- Dosage adjustments were made based on observed toxicity.
Main Results:
- Objective response rates were 23% for IL-2 alone, and 9% for both IFN alone and combination therapy.
- Complete responses were exclusively observed with IL-2 monotherapy.
- Median response duration was 18 months for IL-2 alone, with higher toxicity noted for IL-2 containing regimens.
Conclusions:
- IL-2 and IFN, alone or combined, demonstrate limited activity in advanced RCC patients, even those with indolent disease.
- The findings underscore the urgent need for novel therapeutic approaches in advanced RCC.
- Total IL-2 dose was identified as a predictor of treatment response.